T. L. Loo

621 total citations
27 papers, 522 citations indexed

About

T. L. Loo is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, T. L. Loo has authored 27 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in T. L. Loo's work include Cancer therapeutics and mechanisms (6 papers), Synthesis and Characterization of Heterocyclic Compounds (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). T. L. Loo is often cited by papers focused on Cancer therapeutics and mechanisms (6 papers), Synthesis and Characterization of Heterocyclic Compounds (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). T. L. Loo collaborates with scholars based in United States. T. L. Loo's co-authors include M. Daniel Lane, David P. Rall, Benjamin Drewinko, Jeffrey A. Gottlieb, Mario A. Luna, DavidJ. Stewart, E. J. Freireich, Katherine Lu, Richard M. Caprioli and William E. Seifert and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Life Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

T. L. Loo

27 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. L. Loo United States 10 206 175 115 72 57 27 522
Barbara C. Millar United Kingdom 17 286 1.4× 188 1.1× 101 0.9× 25 0.3× 93 1.6× 36 947
Gerald W. King United States 12 187 0.9× 147 0.8× 102 0.9× 78 1.1× 88 1.5× 16 674
Jane C. Wright United States 14 144 0.7× 215 1.2× 93 0.8× 46 0.6× 30 0.5× 42 490
Meyskens Fl United States 13 478 2.3× 205 1.2× 83 0.7× 35 0.5× 23 0.4× 34 822
Orlando J. Martelo United States 16 306 1.5× 129 0.7× 135 1.2× 76 1.1× 96 1.7× 36 727
P. Schein United States 10 144 0.7× 196 1.1× 61 0.5× 50 0.7× 12 0.2× 18 578
K Csóka Sweden 12 246 1.2× 207 1.2× 47 0.4× 42 0.6× 50 0.9× 19 503
Robert G. Pietrusko United States 10 209 1.0× 127 0.7× 78 0.7× 24 0.3× 17 0.3× 15 607
Alexander Nakeff United States 17 326 1.6× 134 0.8× 127 1.1× 31 0.4× 93 1.6× 56 936
J.R. Bertino United States 16 462 2.2× 221 1.3× 75 0.7× 53 0.7× 55 1.0× 28 925

Countries citing papers authored by T. L. Loo

Since Specialization
Citations

This map shows the geographic impact of T. L. Loo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. L. Loo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. L. Loo more than expected).

Fields of papers citing papers by T. L. Loo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. L. Loo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. L. Loo. The network helps show where T. L. Loo may publish in the future.

Co-authorship network of co-authors of T. L. Loo

This figure shows the co-authorship network connecting the top 25 collaborators of T. L. Loo. A scholar is included among the top collaborators of T. L. Loo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. L. Loo. T. L. Loo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Savaraj, Niramol, et al.. (1992). Pharmacology of intrathecal VP-16-213 in dogs. Journal of Neuro-Oncology. 13(3). 211–5. 10 indexed citations
2.
Lu, Katherine, et al.. (1988). Pharmacokinetics of homoharringtonine in dogs. Cancer Chemotherapy and Pharmacology. 21(2). 139–42. 15 indexed citations
3.
Lu, Katherine, et al.. (1986). Clinical pharmacolinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride. Cancer Chemotherapy and Pharmacology. 16(2). 156–9. 2 indexed citations
4.
Stewart, DavidJ., Zhengang Guo, Katherine Lu, et al.. (1984). Human tissue distribution of 4?-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA). Cancer Chemotherapy and Pharmacology. 12(2). 116–9. 8 indexed citations
5.
Stewart, DavidJ., Katherine Lu, M. E. Leavens, et al.. (1983). Concentrations of vinblastine in human intracerebral tumor and other tissues. Journal of Neuro-Oncology. 1(2). 139–44. 47 indexed citations
6.
Loo, T. L., et al.. (1982). Effects of cimetidine on the clinical pharmacokinetics of 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone (AZQ, NSC-182986). Clinical Pharmacology & Therapeutics. 31(2). 1 indexed citations
7.
Lu, Katherine & T. L. Loo. (1980). The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. Cancer Chemotherapy and Pharmacology. 4(4). 275–9. 7 indexed citations
8.
Benjamin, Robert S., et al.. (1980). ChemInform Abstract: SYNTHESIS AND BIOLOGICAL ACTIVITIES OF FTORAFUR METABOLITES. 3′‐ AND 4′‐HYDROXYFTORAFUR. Chemischer Informationsdienst. 11(5). 1 indexed citations
9.
Valdivieso, Manuel, Ellen Moore, W. Plunkett, et al.. (1980). Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).. PubMed. 64(2-3). 285–92. 12 indexed citations
10.
Plunkett, William, John A. Benvenuto, David J. Stewart, & T. L. Loo. (1979). High-pressure liquid chromatographic analysis of 3-deazauridine-5'-triphosphate in human cancer cells.. PubMed. 63(3). 415–20. 3 indexed citations
11.
Ho, D H, Gerald P. Bodey, S. W. Hall, et al.. (1978). Clinical Pharmacology of Tetrahydrouridine. The Journal of Clinical Pharmacology. 18(5-6). 259–265. 10 indexed citations
12.
Burks, Thomas F., et al.. (1978). Mechanism of the Cardiovascular Actions of Cyclocytidine. Experimental Biology and Medicine. 159(3). 374–379. 2 indexed citations
13.
Benvenuto, John A., D. Farquhar, E. J. Freireich, & T. L. Loo. (1977). Biotransformation of ftorafur (FT, NSC 148958) in man. Proceedings of the American Association for Cancer Research. 18. 2 indexed citations
14.
Hall, S. W., Robert S. Benjamin, A. Clark Griffin, & T. L. Loo. (1976). Pharmacokinetics and metabolism of ftorafur (FT) in man. Proceedings of the American Association for Cancer Research. 17. 2 indexed citations
15.
Drewinko, Benjamin, et al.. (1976). Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells.. PubMed. 1(4). 187–95. 107 indexed citations
16.
Drewinko, Benjamin, T. L. Loo, & Jeffrey A. Gottlieb. (1976). A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells.. PubMed. 36(2 Pt 1). 511–5. 16 indexed citations
17.
Benjamin, Robert S., T. L. Loo, & Jacqueline Friedman. (1975). Liver disease and clinical pharmacology of Baker's antifolate (BAF, NSC 139105). 17(2). 4 indexed citations
18.
Adamson, Richard H., et al.. (1963). Inhibition of dihydrofolate reductase by dichloromethotrexate and its metabolite. Life Sciences. 2(6). 407–409. 6 indexed citations
19.
Adamson, Richard H., T. L. Loo, & Harold P. Morris. (1962). Metabolism of Cl36-Dichloromethotrexate by Transplantable Liver Tumors. Experimental Biology and Medicine. 111(3). 566–568. 2 indexed citations
20.
Rall, David P., et al.. (1957). Appearance and Persistence of Fluorescent Material in Tumor Tissue after Tetracycline Administration<xref ref-type="fn" rid="FN1">2</xref>. JNCI Journal of the National Cancer Institute. 19(1). 79–85. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026